For the millions who live with the quiet devastation of progressive vision loss, science has long offered only partial answers — drugs that slow the damage but cannot always stop it, and sometimes cause harm of their own. Researchers at Scripps Research Institute have now described a different path: a fragment of a protein called CITED2, which in mouse models reduced the rogue blood vessel growth that steals sight while also preserving the healthy vessels the eye depends on. The work, published in the Proceedings of the National Academy of Sciences, does not yet promise a cure, but it opens a
TheHealthSite
· Oct 28, 2020
· health
· 2 min read
Medium
Sourcing: Characterized
Scientists develop promising new treatment to prevent blindness from retinal disease
Millions of people worldwide suffer from retinal diseases that often result in blindness, including age-related macular degeneration and diabetic retinopathy.
◉
Health & Medicine
9175 related articles
FDA Approves Pancreatic Cancer Drug That May Extend Patient Survival
CBS News · 100% match
mRNA COVID Vaccines Show Survival Boost in Advanced Cancer Patients
Devdiscourse · 99% match
Amivantamab-lazertinib combo outperforms standard care in high-risk EG…
News-Medical.net · 99% match
Greater Weight Loss From GLP-1 Drugs Significantly Reduces Obesity-Rel…
News-Medical · 99% match
Researchers call for clinical trials of Paxlovid for long COVID
Reuters · 99% match
Related Coverage
The Guardian · Sep 10
ABC and Guardian condemn One Nation's media ban as democratic threat
Australia's One Nation party has barred the ABC and Guardian from press conferences, drawing accusations of censorship a…
BBC News · Sep 10 Cancer wait times worsen despite government's ambitious treatment targetsCancer wait times in England have deteriorated since the government announced ambitious treatment targets, with performa…
nhl.com · Sep 10 Barry Melrose, NHL Coach and ESPN Hockey Icon, Dies at 70Barry Melrose, the Emmy-winning ESPN hockey analyst and former NHL coach known for his distinctive mullet and flamboyant…
NBC News · Sep 10 Bangladesh measles outbreak kills nearly 1,000 as vaccination gaps widenA measles outbreak in Bangladesh has killed nearly 1,000 children since the start of 2026, with over 166,000 suspected c…
Bias & Framing
⚖
Article presents promising early-stage research with optimistic framing but lacks critical perspective on limitations of animal models and timeline to human application.
Bias Direction
center-right
Confidence
MED
Promotional framing emphasizing breakthrough potential while minimizing scientific uncertainty. Uses hopeful language ('thrilled,' 'promising,' 'hope') and positions new treatment as superior without adequate caveats about developmental stage.
offering hope for patients
uncovered a potential new strategy
highly effective
broader benefits
researchers were thrilled
promising new treatment
Skeptical expert commentary on translating mouse studies to humans
Timeline and regulatory pathway to clinical trials
Potential limitations or risks of the new approach
Cost and accessibility considerations
Comparison of efficacy rates with specific numbers
Patient advocacy group perspectives on unmet needs
Competing research approaches in the field
Geopolitical Impact
🌎
Medical breakthrough in retinal disease treatment has no direct geopolitical implications; this is a domestic scientific advancement with potential global humanitarian benefits.
Escalation Risk
low
Confidence
HIGH
No shifts in international power dynamics. This is a biomedical research development by a US institution with potential universal healthcare applications.
Economic Lens
📈
New CITED2 protein treatment shows promise for retinal diseases by reducing abnormal blood vessel growth while preserving healthy capillaries, potentially addressing limitations of current anti-VEGF therapies.
Market Signal
bullish
Confidence
MED
Pharmaceutical and Biotechnology
Healthcare and Medical Devices
Ophthalmology and Eye Care
Medical Research and Development
Patients with retinal diseases (age-related macular degeneration, diabetic retinopathy) could gain access to more effective treatments with fewer side effects, potentially reducing vision loss and blindness rates while improving quality of life and reducing long-term healthcare costs.
FDA may accelerate approval pathways for promising ophthalmology treatments; healthcare systems may need to evaluate reimbursement strategies; potential for expanded coverage of advanced retinal disease treatments; regulatory frameworks may evolve to accommodate novel protein-based therapies.